                         SEQUENCE LISTING

<110>  IMMUTHER PHARMTECH (SHANGHAI) CO., LTD.
 
<120>  Anti-ROR1 antibodies and preparation method and uses thereof

<130>  P2019-1976

<160>  42    

<170>  PatentIn version 3.5

<210>  1
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of antibody C3

<400>  1

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Leu Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Tyr Met His Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Gly Arg Leu Thr Ile Ser Val Asp Thr Ser Thr Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Gly Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Tyr Tyr Tyr His Asp Ser Ser Gly Tyr Tyr Ser Tyr Phe Asp Tyr 
            100                 105                 110         


Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120             


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1

<400>  2

Ser Tyr Tyr Trp Ser 
1               5   


<210>  3
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2

<400>  3

Tyr Met His Tyr Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Gly 
1               5                   10                  15      


<210>  4
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3

<400>  4

Tyr Tyr Tyr His Asp Ser Ser Gly Tyr Tyr Ser Tyr Phe Asp Tyr 
1               5                   10                  15  


<210>  5
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of antibody C3

<400>  5

Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  6
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1

<400>  6

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  7
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2

<400>  7

Asp Ala Ser Asn Arg Ala Ser 
1               5           


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3

<400>  8

Gln Gln Arg Ser Asn Trp Pro Pro Thr 
1               5                   


<210>  9
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1

<400>  9

Gly Gly Ser Ile Ser Ser Tyr Tyr 
1               5               


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2

<400>  10

Met His Tyr Ser Gly Ser Thr 
1               5           


<210>  11
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3

<400>  11

Ala Arg Tyr Tyr Tyr His Asp Ser Ser Gly Tyr Tyr Ser Tyr Phe Asp 
1               5                   10                  15      


Tyr 
    


<210>  12
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1

<400>  12

Gln Ser Val Ser Ser Tyr 
1               5       


<210>  13
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2 and FR3 of VL

<400>  13

Asp Ala Ser Asn Arg Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser 
1               5                   10                  15      


Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 
            20                  25                  30          


Asp Phe Ala Val Tyr Tyr Cys 
        35                  


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3

<400>  14

Gln Gln Arg Ser Asn Trp Pro Pro Thr 
1               5                   


<210>  15
<211>  121
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of antibody G3

<400>  15

Gln Val Gln Leu Gln Gln Trp Gly Ala Gly Leu Leu Lys Pro Ser Glu 
1               5                   10                  15      


Thr Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr 
            20                  25                  30          


Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 
        35                  40                  45              


Gly Glu Ile Asn His Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys 
    50                  55                  60                  


Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu 
65                  70                  75                  80  


Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Gly His Ser Ser Gly Trp Tyr Arg Arg Tyr Phe Asp Leu Trp Gly 
            100                 105                 110         


Arg Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     


<210>  16
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1

<400>  16

Gly Tyr Tyr Trp Ser 
1               5   


<210>  17
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2

<400>  17

Glu Ile Asn His Ser Gly Ser Thr Ser Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      


<210>  18
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3

<400>  18

Gly His Ser Ser Gly Trp Tyr Arg Arg Tyr Phe Asp Leu 
1               5                   10              


<210>  19
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of antibody G3

<400>  19

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 
1               5                   10                  15      


Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Lys Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 
65                  70                  75                  80  


Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser Asn Trp Pro Pro 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
            100                 105         


<210>  20
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1

<400>  20

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala 
1               5                   10      


<210>  21
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2

<400>  21

Asp Ala Ser Asn Arg Ala Thr 
1               5           


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3

<400>  22

Gln Gln Arg Ser Asn Trp Pro Pro Thr 
1               5                   


<210>  23
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1

<400>  23

Gly Gly Ser Phe Ser Gly Tyr Tyr 
1               5               


<210>  24
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2

<400>  24

Ile Asn His Ser Gly Ser Thr 
1               5           


<210>  25
<211>  15
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3

<400>  25

Ala Arg Gly His Ser Ser Gly Trp Tyr Arg Arg Tyr Phe Asp Leu 
1               5                   10                  15  


<210>  26
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1

<400>  26

Gln Ser Val Ser Ser Tyr 
1               5       


<210>  27
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2 and FR3 of VL

<400>  27

Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Lys Phe Ser Gly Ser 
1               5                   10                  15      


Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu 
            20                  25                  30          


Asp Phe Ala Val Tyr Tyr Cys 
        35                  


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3

<400>  28

Gln Gln Arg Ser Asn Trp Pro Pro Thr 
1               5                   


<210>  29
<211>  123
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH of antibody G6

<400>  29

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ser Leu Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Arg Asp Asn Trp Asn Asp Val Tyr Tyr Tyr Tyr Gly Met Asp Val 
            100                 105                 110         


Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 
        115                 120             


<210>  30
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1

<400>  30

Asp Tyr Ala Met His 
1               5   


<210>  31
<211>  17
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2

<400>  31

Leu Ile Ser Gly Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys 
1               5                   10                  15      


Gly 
    


<210>  32
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3

<400>  32

Asp Asn Trp Asn Asp Val Tyr Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10                  


<210>  33
<211>  107
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL of antibody G3

<400>  33

Asp Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Ile Gly 
1               5                   10                  15      


Asp Thr Val Thr Ile Ser Cys Gln Ala Ser Arg Asp Ile Ser Asp Tyr 
            20                  25                  30          


Leu Asn Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Ala Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Lys Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Asp Asp Leu Leu Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys 
            100                 105         


<210>  34
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1

<400>  34

Gln Ala Ser Arg Asp Ile Ser Asp Tyr Leu Asn 
1               5                   10      


<210>  35
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2

<400>  35

Asp Ala Ser Asn Leu Ala Thr 
1               5           


<210>  36
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3

<400>  36

Gln Gln Asp Asp Leu Leu Pro Leu Thr 
1               5                   


<210>  37
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR1

<400>  37

Gly Phe Thr Phe Asp Asp Tyr Ala 
1               5               


<210>  38
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR2

<400>  38

Ile Ser Gly Asp Gly Gly Ser Thr 
1               5               


<210>  39
<211>  16
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VH-CDR3

<400>  39

Ala Arg Asp Asn Trp Asn Asp Val Tyr Tyr Tyr Tyr Gly Met Asp Val 
1               5                   10                  15      


<210>  40
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR1

<400>  40

Arg Asp Ile Ser Asp Tyr 
1               5       


<210>  41
<211>  39
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR2 and FR3 of  VL

<400>  41

Asp Ala Ser Asn Leu Ala Thr Gly Val Pro Ser Arg Phe Ser Gly Ser 
1               5                   10                  15      


Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Lys Ser Leu Gln Pro Glu 
            20                  25                  30          


Asp Val Ala Thr Tyr Phe Cys 
        35                  


<210>  42
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  VL-CDR3

<400>  42

Gln Gln Asp Asp Leu Leu Pro Leu Thr 
1               5                   


